Peter Van Vlasselaer, will become executive chairman of iPierian after he replaced former CEO Michael Venuti, after the latter's brief tenure, in May.
Nancy Stagliano (pictured) has joined iPierian, a US-based stem cell medical development company backed by drugs company GlaxoSmithKline, as chief executive (CEO) after her previous role as CEO and co-founder of CytomX Therapeutics.
Peter Van Vlasselaer, will become executive chairman of iPierian after he replaced former CEO Michael Venuti, after the latter’s brief tenure, in May. Van Vlasselaer was the former CEO of Arresto Bioscience.
GlaxoSmithKline’s corporate venturing division SR One and Biogen Idec’s $200m New Ventures unit alongside undisclosed…
